Structural basis of species-specific infectivities of two prion strains
两种朊病毒株物种特异性感染性的结构基础
基本信息
- 批准号:7843591
- 负责人:
- 金额:$ 7.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-15 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmino Acid SequenceAmyloidAmyloid fibersBacteriaBe++ elementBehaviorBerylliumBiologicalCandida albicansCattleCell physiologyChimera organismComplexCysteineDataDefectDiseaseElementsEncephalopathiesEventGoalsHumanIn VitroInvestigationLocationMammalsMolecular ConformationNamesNatureNeurodegenerative DisordersParkinson DiseasePeptidesPlasmidsPrion DiseasesPrionsProcessPropertyProteinsRecombinantsRelative (related person)ResearchSaccharomyces cerevisiaeSeminalSite-Directed MutagenesisSocietiesSolventsStructureTestingTherapeuticVariantWorkYeastsbaseconformerfluorophorein vivomutantpreventprion-likeprotein aggregationprotein foldingpublic health relevancesup35three dimensional structuretransmission processyeast prion
项目摘要
DESCRIPTION (provided by applicant): Prions are infectious proteins that cause devastating neurodegenerative diseases (transmissible encephalopathies) in humans, cattle and other mammals. A puzzling aspect of these proteins is that they form not only a single 2-sheet rich conformation, but a suite of related aggregated conformers that are responsible for different prion diseases. Naturally occurring prions in yeast also display very similar behavior. A key aspect of different prion strains in both mammals and yeast is that they have unique capacities for traversing species barriers, which is poorly understood but has broad biological importance. The goal of this proposal is to investigate how differences in the structure of infectious prion conformers govern their ability to establish and overcome species barriers. Unfortunately, it is currently not possible to form highly infectious prions from recombinant mammalian prion protein (PrP) for structural studies, but this is readily possible for yeast prions. Therefore, we propose to investigate the structural relationship between prion strains and species barriers for the yeast prion Sup35 from S. cerevisiae (Sc) and C. albicans (Ca). A robust prion species barrier exists between Sc and Ca Sup35, but a Sup35 chimera composed of domains from both species can overcome this barrier. Using peptide microarrays we discovered that the capacity of chimeric prions to overcome this barrier is encoded by two small elements of primary sequence (named "recognition elements"), one from each yeast species (Tessier & Lindquist, Nature, 2007). The key hypothesis we propose to test is that the species-specific infectivities of two different prion strains are due to differences in the location of the prion recognition elements relative to the amyloid core. For the chimeric strain specific for infecting S. cerevisiae, we hypothesize that the Sc Sup35 recognition element is within the amyloid core (solvent shielded) while the Ca Sup35 recognition element is either outside the amyloid core (solvent exposed) or in an incompetent, non-amyloid conformation (weakly solvent shielded), and vice versa for the other strain conformation. We propose to test this hypothesis through the following three specific aims: 1) To generate single cysteine mutants in the prion domain of the Sup35 chimera in both bacterial and yeast expression plasmids, 2) To evaluate if single cysteine mutants have the same prion properties as the wild-type chimera by characterizing their prion behavior both in vitro and in vivo, and 3) To determine the degree of solvent exposure of cysteines in each strain conformation of the chimeric prion. The data obtained in this study will provide important structural information on how the locations of key amino acid sequences relative to the prion amyloid core impact the capacities of prions to overcome species barriers. Moreover, these findings will inform investigations of mammalian prions by providing testable hypotheses of how different mammalian prion strains traverse species barriers. PUBLIC HEALTH RELEVANCE: The transmission of infectious prions from cattle to humans continues to threaten our society. Prions form multiple infectious strain conformations that have unique capacities to overcome species barriers through an unknown mechanism. This proposed research aims to decipher this mechanism with the long-term goal of rationally developing therapeutics to prevent and reverse interspecies prion transmission.
描述(申请人提供):Pron是一种传染性蛋白质,在人类、牛和其他哺乳动物中会导致毁灭性的神经退行性疾病(传播性脑病)。这些蛋白质的一个令人费解的方面是,它们不仅形成一个单一的两页丰富的构象,而且形成一套相关的聚集构象,这些构象与不同的Pron疾病有关。酵母中自然产生的普恩也表现出非常相似的行为。哺乳动物和酵母中不同的Pron菌株的一个关键方面是它们具有独特的穿越物种障碍的能力,这一点人们知之甚少,但具有广泛的生物学意义。这项提议的目的是调查传染性普恩构象的结构差异如何支配它们建立和克服物种障碍的能力。不幸的是,目前还不可能从重组哺乳动物普恩蛋白(PrP)中形成高感染性的普恩蛋白用于结构研究,但对于酵母普恩蛋白来说,这是很容易实现的。因此,我们建议研究来自酿酒酵母(SC)和白色念珠菌(CA)的酵母Pron Sup35的Pron菌株之间的结构关系和物种屏障。Sc和CaSup35之间存在强大的Prion物种障碍,但由两个物种的结构域组成的Sup35嵌合体可以克服这一障碍。利用多肽微阵列,我们发现嵌合普鲁恩克服这一障碍的能力是由两个初级序列的小元素(称为“识别元素”)编码的,每个酵母物种一个(Tessier&Lindquist,自然,2007)。我们建议检验的关键假设是,两个不同的Pron菌株的物种特异性感染性是由于Prion识别元件相对于淀粉样蛋白核心的位置不同所致。对于感染酿酒酵母的嵌合菌株,我们假设SC Sup35识别元件在淀粉样蛋白核心内(溶剂屏蔽),而Ca Sup35识别元件要么在淀粉样蛋白核心外(暴露在溶剂中),要么处于不起作用的非淀粉样构象(弱溶剂屏蔽),对于另一株菌株构象反之亦然。我们建议通过以下三个具体目标来验证这一假说:1)在细菌和酵母表达载体中在Sup35嵌合体的Prion结构域中产生单个半胱氨酸突变体,2)通过表征它们在体外和体内的Prion行为来评估单个半胱氨酸突变体是否具有与野生型嵌合体相同的Prion特性,以及3)确定半胱氨酸在嵌合Prion构象的每个菌株中的溶剂暴露程度。这项研究中获得的数据将提供重要的结构信息,说明关键氨基酸序列相对于Prion淀粉样蛋白核心的位置如何影响Prion克服物种障碍的能力。此外,这些发现将通过提供关于不同哺乳动物Pron菌株如何跨越物种障碍的可测试假说,为哺乳动物Prion的研究提供信息。公共卫生相关性:传染性普恩病毒从牛到人的传播继续威胁着我们的社会。Pron形成多种感染性菌株构象,这些构象具有通过未知机制克服物种障碍的独特能力。这项拟议的研究旨在破译这一机制,长期目标是合理开发治疗方法,以防止和逆转普恩病毒的跨物种传播。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β.
- DOI:10.1002/cbic.201100123
- 发表时间:2011-07-25
- 期刊:
- 影响因子:3.2
- 作者:Ladiwala, Ali Reza A.;Mora-Pale, Mauricio;Lin, Jason C.;Bale, Shyam Sundhar;Fishman, Zachary S.;Dordick, Jonathan S.;Tessier, Peter M.
- 通讯作者:Tessier, Peter M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter M Tessier其他文献
Peter M Tessier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter M Tessier', 18)}}的其他基金
Neuronal Silencing of ATXN3 Using Peripherally Administered Antibody/ASO Conjugates That Penetrate the Blood-Brain Barrier
使用可穿透血脑屏障的外周给药抗体/ASO 缀合物对 ATXN3 进行神经元沉默
- 批准号:
10646563 - 财政年份:2023
- 资助金额:
$ 7.17万 - 项目类别:
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern
SARS-CoV-2 相关变体的受体亲和力与抗体逃逸之间权衡的突变分析
- 批准号:
10510890 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern
SARS-CoV-2 相关变体的受体亲和力与抗体逃逸之间权衡的突变分析
- 批准号:
10647809 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位
- 批准号:
10387799 - 财政年份:2020
- 资助金额:
$ 7.17万 - 项目类别:
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位
- 批准号:
10599101 - 财政年份:2020
- 资助金额:
$ 7.17万 - 项目类别:
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregates
结构引导抗体靶向淀粉样蛋白聚集体中预先选择的表位
- 批准号:
10372055 - 财政年份:2020
- 资助金额:
$ 7.17万 - 项目类别:
Design of Antibody Fragments Specific For Amyloidogenic Aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
- 批准号:
9582129 - 财政年份:2014
- 资助金额:
$ 7.17万 - 项目类别:
Design of antibody fragments specific for amyloidogenic aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
- 批准号:
8823800 - 财政年份:2014
- 资助金额:
$ 7.17万 - 项目类别:
Design of antibody fragments specific for amyloidogenic aggregates
淀粉样蛋白形成聚集物特异性抗体片段的设计
- 批准号:
8631424 - 财政年份:2014
- 资助金额:
$ 7.17万 - 项目类别:
Structural basis of species-specific infectivities of two prion strains
两种朊病毒株物种特异性感染性的结构基础
- 批准号:
7641394 - 财政年份:2009
- 资助金额:
$ 7.17万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 7.17万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 7.17万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 7.17万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 7.17万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 7.17万 - 项目类别: